ProStrakan's Agreement With Novartis Could Reach $140M

LONDON - ProStrakan Group plc sealed a deal with a headline value of $140 million under which Novartis AG will develop antibody treatments for bone-related diseases using a ProStrakan target. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)